about
Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?Acute hemolysis with acute renal failure in a patient with valproic acid poisoning treated with charcoal hemoperfusionValproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.Hyperammonemic Encephalopathy due to Valproic Acid and Topiramate Interaction.Endocrine, metabolic, nutritional, and toxic disorders leading to dementia.Pronounced reversible hyperammonemic encephalopathy associated with combined valproate-topiramate therapy in a 7-year-old girl.A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver.A reversible cause of coma in epilepsyValproic Acid-Induced Hyperammonemic Encephalopathy as a Cause of Neurologic Deterioration after Unruptured Aneurysm Surgery.Endocrine and metabolic changes in epileptic patients receiving valproic acid.The Effect of Carnitine Supplementation on Hyperammonemia and Carnitine Deficiency Treated with Valproic Acid in a Psychiatric Setting.Valproate Induced Hyperammonemic Delirium.Two cases of valproic acid poisoning treated with L-carnitine.Glucose metabolism as a target of histone deacetylase inhibitors.Hyperammonemia: What Urea-lly Need to Know: Case Report of Severe Noncirrhotic Hyperammonemic Encephalopathy and Review of the Literature.Valproic Acid-induced hyperammonemia in the elderly: a review of the literatureCarnitine in the treatment of valproic acid-induced toxicity.Noncirrhotic hyperammonaemic encephalopathy.Hyperammonemic coma after craniotomy: Hepatic encephalopathy from upper gastrointestinal hemorrhage or valproate side effect?: Case report and literature review.Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection.Valproate Induced Delirium due to Hyperammonemia in a Case of Acute Mania: A Diagnostic DilemmaValproate-associated reversible encephalopathy in a 3-year-old girl with Pallister-Killian syndrome.Valproate monotherapy induced-delirium due to hyperammonemia: A report of three adult cases with different types of presentation.Valproate-induced hyperammonemic encephalopathy: a case reportValproate-induced hyperammonemic encephalopathy: A reminder of rare complication of valproate.Non-hyperammonaemic valproate encephalopathy after 20 years of treatment.Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.Valproic Acid-induced myoclonus in a demented patient: a case report.J-refocused coherence transfer spectroscopic imaging at 7 T in human brain.Valproic acid-induced encephalopathy in very long course treated patients.Possible new clinical sign of hyperammonemia.Serum and muscle carnitine levels in epileptic children receiving sodium valproate.Valproate-induced hyperammonemic encephalopathy treated by hemodialysis.[Hyperammonemia secondary to the use of valproic acid: case report].Acute hyperammonemic coma with chronic valproic acid therapy.Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.Fatal valproate overdose in a newborn baby.The pharmacogenomics of valproic acid.Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children.Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.
P2860
Q24813193-04845DDD-A2AB-47C2-BA24-93ED080CE574Q28248969-2F1F11FE-8321-41FF-9D87-BA71D8697C2AQ33362174-EE43B8E6-E021-4E0B-9CA7-F84B606EE8BFQ34022325-555112FD-D98E-4650-8A7B-19F7312D03B2Q34574924-E5F86E60-3D06-4710-8979-5A4B040F1B72Q35748734-AAB42A8C-39BE-4CE0-AEEF-6B7FD2A37136Q35968146-60C90555-70F1-40F8-AC2D-E358CDC93E78Q35982984-63C78977-1AB1-4AA9-B5E7-9AB16DFC5823Q36044122-1AD30789-BE38-42C6-935D-1645CC659F82Q36142002-C567139E-C352-420E-AA14-40ABCC5E78A1Q36307063-F7ADCD4E-7E70-4009-860B-874E36C1B22CQ36476422-A3BA3426-9685-491D-A233-7E87C04A63B8Q37122831-BC61E238-3BBB-4AE5-88D8-682FA0814BFCQ37125470-BC6E4C39-12C1-42E3-984D-5270C0699A61Q37310462-4AF04F42-9981-40AE-9701-30EC30E80F62Q37317489-5718B8B9-EA8F-45F2-951B-0A36740D4E4DQ37413086-D497E21F-CF95-46B0-B511-308F0194F523Q37899941-127D648B-C193-4008-9B28-6C588E86164EQ39237964-B76FA085-84EE-412B-91BE-A7C0633E37BBQ40528820-594316AC-D647-4035-BEA3-2BCE3B3A9838Q40833111-855B6FFE-66AB-4F6E-BBEE-89393AD6EFF5Q41360043-CC04BA83-3FA0-42C3-AF12-314EFA18029DQ41886184-7049B5A6-111C-41E2-8408-FFB490EC33C6Q41991348-91C956B1-E62E-415F-BC97-ABB61CE836A9Q42010705-0DAF6FB5-09CF-4C8D-8956-1D40704D32D2Q42016846-06A489D7-F27E-487C-BBC3-56AF2DA3B516Q42128344-4FCC1F47-B561-4E2B-A5BE-6C9004D5ECE3Q42175879-6203E91E-A7EB-406F-B204-EB119A2B2AD7Q42962994-730340DB-B63A-48A2-803A-9D1172A6A3E5Q43260855-A474F03E-9157-4199-9DBC-CBA37B0D1984Q45911800-1F79DCEA-5F66-4C67-96F5-F2ED824AB06DQ46147751-52E412BA-13BD-4540-B0B6-BF024A4B7F26Q46367536-191B25A1-1102-4A87-9E4C-0BAC52FBFC19Q46650907-640AAC61-2CEF-41BA-B789-6ACFB5670982Q46803792-79984A34-0B17-4F1F-A2E5-480EAEC2A730Q48091925-01274962-4174-4958-89F3-D807651C449BQ48109083-3238FD17-9337-4AFD-8324-940F0B4964F2Q50212278-ECF3F2BA-35AB-4226-884A-CA781E6CE9F6Q51598500-37AB8B17-D19B-4713-A8DF-D73E1A7AE01BQ53061700-EBD3FDA7-EBAD-4A8D-8AEE-E1506BB159F8
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Valproate-induced hyperammonemic encephalopathy.
@ast
Valproate-induced hyperammonemic encephalopathy.
@en
type
label
Valproate-induced hyperammonemic encephalopathy.
@ast
Valproate-induced hyperammonemic encephalopathy.
@en
prefLabel
Valproate-induced hyperammonemic encephalopathy.
@ast
Valproate-induced hyperammonemic encephalopathy.
@en
P2093
P356
P1476
Valproate-induced hyperammonemic encephalopathy.
@en
P2093
Alberto Verrotti
Daniela Trotta
Francesco Chiarelli
Guido Morgese
P2888
P304
P356
10.1023/A:1021918104127
P577
2002-12-01T00:00:00Z
P6179
1029611789